OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder
- Conditions
- Bipolar I DisorderManic Episode
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2020-02-10
- Target Recruit Count
- 322
- Registration Number
- NCT03259555
- Locations
- 🇺🇸
Galiz Research, Hialeah, Florida, United States
🇺🇸Ci Trials, Riverside, California, United States
🇺🇸Richard H Weisler, MD, PA, and Associates, Raleigh, North Carolina, United States
A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder
- Conditions
- Bipolar I DisorderManic Episode
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2020-02-11
- Target Recruit Count
- 333
- Registration Number
- NCT03257865
- Locations
- 🇺🇸
CiTrials, Santa Ana, California, United States
🇺🇸Research Centers of America LLC, Hollywood, Florida, United States
🇺🇸CNRI-San Diego, San Diego, California, United States
Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2025-05-15
- Target Recruit Count
- 295
- Registration Number
- NCT03238326
- Locations
- 🇵🇱
Clinical Research Site #272, Poznań, Poland
🇵🇱Clinical Research Site #270, Walbrzych, Poland
🇵🇱Clinical Research Site #267, Wrocław, Poland
Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2023-12-20
- Target Recruit Count
- 316
- Registration Number
- NCT03198078
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, Oklahoma City, Oklahoma, United States
Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2018-06-12
- Target Recruit Count
- 36
- Registration Number
- NCT03150771
- Locations
- 🇺🇸
Community Clinical Research Inc., Austin, Texas, United States
🇺🇸CNRI-San Diego, San Diego, California, United States
🇺🇸Woodland International Research Group, Little Rock, Arkansas, United States
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury
- Conditions
- Neurobehavioral Disinhibition
- Interventions
- Drug: PlaceboDrug: AVP-786-28Drug: AVP-786-42.63
- First Posted Date
- 2017-03-29
- Last Posted Date
- 2023-09-29
- Target Recruit Count
- 168
- Registration Number
- NCT03095066
- Locations
- 🇺🇸
Design Neuroscience Center, PL, Doral, Florida, United States
🇺🇸Meridien Research, Maitland, Florida, United States
🇺🇸Neurobehavioral Medicine Group #222, Bloomfield Hills, Michigan, United States
A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)
- Conditions
- Stress Disorders, Post-Traumatic
- Interventions
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2021-12-08
- Target Recruit Count
- 336
- Registration Number
- NCT03033069
- Locations
- 🇺🇸
Investigational Site, Everett, Washington, United States
An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2024-07-05
- Target Recruit Count
- 157
- Registration Number
- NCT02970929
- Locations
- 🇺🇸
CNRI-Los Angeles, LLC, Pico Rivera, California, United States
🇺🇸Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸UCSD Medical Center UCSD Department of Psychiatry, San Diego, California, United States
A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2024-07-05
- Target Recruit Count
- 245
- Registration Number
- NCT02969382
- Locations
- 🇷🇴
Spitalul Clinic de Neuropsihiatrie Craiova, Craiova, Romania
🇺🇸Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸California Neuropsychopharmacology Clinical Research Institute-LA, LLC(CNRI- LA, LLC), Pico Rivera, California, United States
A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis
- Conditions
- Parkinson Disease Psychosis
- Interventions
- Drug: Placebo capsule
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2024-07-05
- Target Recruit Count
- 39
- Registration Number
- NCT02969369
- Locations
- 🇺🇸
Keck School of Medicine of USC/ University of Southern California, Los Angeles, California, United States
🇺🇸University of Miami, Dept. of Neurology, Miami, Florida, United States
🇺🇸The Emory Clinic, Atlanta, Georgia, United States